SNDX - Syndax Pharma falls after updating early-stage data for leukemia therapy

Syndax Pharmaceuticals (SNDX -16.0%) has dropped over 10% after the company shared updated data from a Phase 1/2 trial for SNDX-5613 in patients with mutant relapsed/refractory (R/R) acute leukemias. In the AUGMENT-101 trial that included patients with MLLr and NPM1c mutation, the composite complete response ((CRc)) was 44% among 45 patients who received the therapy at the data cut off on June 29. 70% of them showed no evidence of minimal residual disease (MRD-). After a median follow up only 3.2 months, the patients were cancer free for 5.2 months – the median duration of complete response (CR) or CR with partial hematologic recovery (CRh). Thirteen patients remained on the trial as of the data cutoff and the drug appeared to be safe and well tolerated with no study discontinuations due to any adverse effects. More data will be part of the oral presentation scheduled at the upcoming 63rd American

For further details see:

Syndax Pharma falls after updating early-stage data for leukemia therapy